Form 4: Checkpoint Therapeutics CEO James Oliviero Sells Shares to Cover Tax Obligations and Transfers Shares to Irrevocable Trust

CEO James Oliviero sold shares to cover tax obligations related to vesting restricted stock and transferred shares to an irrevocable trust for his children.

Summary

• On June 26, 2024, James F. Oliviero III, CEO, President, and Director of Checkpoint Therapeutics, Inc., sold 24,610 shares of common stock at a weighted average price of $2.05 to cover tax obligations related to vesting restricted stock.
• The sale was executed automatically by the company's restricted stock administrator, and Mr. Oliviero had no discretion over the transaction.
• Additionally, on the same day, Mr. Oliviero transferred 37,890 shares of common stock to an irrevocable trust for the benefit of his minor children.
• Mr. Oliviero is not a trustee and has no investment control over the securities held by the trust.
• Following these transactions, Mr. Oliviero directly owns 1,939,280 shares of Checkpoint Therapeutics common stock, which includes restricted stock vesting over various time periods.

Sentiment

Score: 5

Explanation: The document describes routine transactions (tax obligation sales and trust transfer) with no inherent positive or negative implications for the company's outlook.

Industry Context

This filing is a routine disclosure of insider transactions. It is common for executives to sell shares to cover tax obligations related to vesting equity awards and to engage in estate planning activities such as transferring assets to trusts.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although it is likely viewed as a routine transaction.
• The transfer of shares to a trust has no direct impact on stakeholders.

Key Dates